PT  - JOURNAL ARTICLE
AU  - Shahla Shojaei
AU  - Javad Alizadeh
AU  - James Thliveris
AU  - Navid Koleini
AU  - Elissavet Kardami
AU  - Grant M Hatch
AU  - Fred Xu
AU  - Sabine Hombach-Klonisch
AU  - Thomas Klonisch
AU  - Saeid Ghavami
TI  - Statins: a new approach to combat temozolomide chemoresistance in glioblastoma
AID  - 10.1136/jim-2018-000874
DP  - 2018 Dec 01
TA  - Journal of Investigative Medicine
PG  - 1083--1087
VI  - 66
IP  - 8
4099  - http://hw-f5-jim.highwire.org/content/66/8/1083.short
4100  - http://hw-f5-jim.highwire.org/content/66/8/1083.full
SO  - J Investig Med2018 Dec 01; 66
AB  - Patients with glioblastoma multiforme (GBM) have an average life expectancy of approximately 15 months. Recently, statins have emerged as a potential adjuvant cancer therapy due to their ability to inhibit cell proliferation and induce apoptosis in many types of cancer. The exact mechanisms that mediate the inhibitory actions of statins in cancer cells are largely unknown. The purpose of this proceeding paper is to discuss some of the known anticancer effects of statins, while focusing on GBM therapy that includes adjunct therapy of statins with chemotherapeutic agents.